Wednesday, August 5, 2009
9:00 a.m. EDT
1-800-731-5774
Webcast: http://www.nucryst.com/web_casts.htm
The briefing, via conference call, is set for
The briefing will be recorded and available for re-broadcast on demand for seven days by dialing 1-877-289-8525. Callers will need to provide the operator with the following reservation number: 21309904 followed by the number sign. An audio file of the call will also be archived on the NUCRYST web site.
About NUCRYST Pharmaceuticals
NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101, for use in medical devices and as an active pharmaceutical ingredient.
Acticoat(TM) is a trademark of Smith & Nephew plc SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
SOURCE NUCRYST Pharmaceuticals Corp.